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Giuseppe Badalamenti1, Angela Listì1, Leonardo Gulotta4, Marta Castiglia1, Fabio Fulfaro1, 
Viviana Bazan1 & Antonio Russo1
This pooled analysis aims at evaluating the diagnostic accuracy of circulating tumor (ct) DNA for the 
detection of EGFR-T790M mutation in NSCLC patients who progressed after EGFR-TKIs. Data from all 
published studies, reporting both sensitivity and specificity of plasma-based EGFR-T790M mutation 
testing by ctDNA were collected by searching in PubMed, Cochrane Library, American Society of Clinical 
Oncology, European Society of Medical Oncology and World Conference of Lung Cancer meeting 
proceedings. A total of twenty-one studies, with 1639 patients, were eligible. The pooled sensitivity of 
ctDNA analysis was 0.67 (95% CI: 0.64–0.70) and the pooled specificity was 0.80 (95% CI: 0.77–0.83). 
The pooled positive predictive value (PPV) was 0.85 (95% CI: 0.82–0.87) and the pooled negative 
predictive value (NPV) was 0.60 (95% CI: 0.56–0.63). The positive likelihood ratio (PLR) and negative 
likelihood ratio (NLR) were 2.67 (95% CI: 1.86–3.82) and 0.46 (95% CI: 0.38–0.54), respectively. The 
pooled diagnostic odds ratio (DOR) was 7.27 (4.39–12.05) and the area under the curve (AUC) of the 
summary receiver operating characteristics (sROC) curve was 0.77. The ctDNA analysis represents a 
promising, non-invasive approach to detect and monitor the T790M mutation status in NSCLC patients. 
Development of standardized methodologies and clinical validation are recommended.
The identification of epidermal growth factor receptor (EGFR) activating mutations as targetable oncogene driv-
ers produced a paradigm shift in the treatment of lung cancer, leading to a personalized approach according to 
the patients’ genomic profile. Several randomized phase III trials1–8 demonstrated a significant survival benefit of 
EGFR-tyrosine kinase inhibitors (TKIs) over platinum-chemotherapy for naïve patients with advanced non-small 
cell lung cancer (NSCLC) carrying exon 19 deletion or exon 21 L858R point mutation. These data led to the 
clinical approval of first and second-generation TKIs as new standard upfront therapy in about 40% of Asian and 
12% of Caucasian “EGFR-positive” NSCLC patients9. Unfortunately, although the great benefit obtained with the 
EGFR-TKIs, cancer cells inevitably develop resistance, commonly within a median time on treatment of 10–12 
months, leading to treatment discontinuation as consequence of disease progression. Among the multiple molec-
ular mechanisms responsible for the occurrence of acquired resistance, the secondary T790M point mutation 
in exon 20 has been identified in about 50–60% of tumor samples after TKI treatment, emerging as the leading 
cause of disease progression10,11. Recently, the scientific community of oncologists has celebrated the advent of 
the first new-generation EGFR-TKI osimertinib in clinical setting. This compound, differently from the other 
drugs, is able to selectively target and inhibit not only EGFR activating mutations, but also the resistant T790M 
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mutation12. The randomized phase III AURA trial showed a significant survival benefit along with a more toler-
able safety profile in favour of osimertinib over platinum-chemotherapy in patients with advanced NSCLC who 
progressed to prior EGFR-TKIs and were T790M-positive13. After the clinical approval of osimertinib as new 
standard of care in T790M-positive NSCLC patients who received prior EGFR-TKIs, re-biopsy at progression 
became mandatory, in order to evaluate T790M status and ultimately personalize second-line treatment. Even if 
tumor tissue biopsy has been considered the gold-standard practice for a long time, however it is associated with 
several limitations, including the invasiveness of procedures, low patients’ compliance, lengthy turnaround time 
and intra-tumor heterogeneity. Furthermore, it often produces inadequate material for mutational testing. The 
detection of EGFR mutations by circulating tumor (ct) DNA has recently emerged as a valid and non-invasive 
alternative approach, overall showing a high concordance with the standard tissue genotyping14–16. Oxnard et 
al. first showed that plasma genotyping by droplet digital PCR (ddPCR) was associated with 70% of sensitivity 
and 69% of specificity as compared to standard tumor tissue analysis of EGFR-T790M mutation in about 60 
NSCLC patients with acquired resistance to EGFR-TKIs17. After that, several other studies investigated the diag-
nostic accuracy of ctDNA in NSCLC patients who progressed to prior EGFR-TKIs, showing a very wide range 
of concordance rate with the tumor tissue analysis18–35. Furthermore the low number of patients included in the 
majority of such studies has limited both the statistical significance and the scientific reliability of results. Thus to 
date the diagnostic accuracy of plasma ctDNA analysis for the detection of EGFR-T790M remains still unclear. 
The aim of this pooled analysis is to combine and analyze simultaneously all the studies comparing ctDNA to 
tumor tissues based T790M-genotyping in order to provide a more precise estimation of the diagnostic accuracy 
of ctDNA analysis in patients with EGFR-mutant advanced NSCLC.
Results
Characteristics of eligible studies. The search of literature updated in March 2018, identified a total of 
1295 records. Among these only nineteen studies met our inclusion criteria and were included in the pooled-anal-
ysis (Fig. 1). The studies by Karlovic20 and Thress19 performed the EGFR-T790M mutation analysis by both real 
time-PCR (RT-PCR) and digital-PCR (dPCR) and the data were reported as two independent studies. Thus 
overall twenty-one eligible studies (1639 patients) were included in the final analysis. All these studies collected 
matched blood and tumor tissue from patients with histologically-confirmed diagnosis of advanced NSCLC who 
progressed to prior EGFR-TKI. The dPCR was the most frequent technology used to detect EGFR-T790M in 
12/21 studies, followed by RT-PCR used in 6/21 studies, and next generation sequencing (NGS) used in 3/21 
studies. The studies used different thresholds of positivity, including mutant allele concentration (copies/ml), 
Figure 1. Flow-chart of Trials Selection.
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mutant allele fraction (%), and number of droplets, whereas the threshold of positivity was not reported in 8 of 
included trials. The sample sizes of the analyzed population ranged from 10 to 543 patients. All the studies ana-
lyzed both sensitivity and specificity of ctDNA analysis for the detection of EGFR-T790M mutation as compared 
to the gold standard tumor tissue. The sensitivity of ctDNA analysis ranged from 40% to 93% and the specificity 
from 18% to 100% across the different studies. The characteristics of the included trials are described in Table 1.
Diagnostic accuracy analysis. The pooled sensitivity of ctDNA was 0.67 (95% CI: 0.64–0.70) and the 
pooled specificity was 0.80 (95% CI: 0.77–0.83) (Fig. 2). The pooled positive predictive value (PPV) of ctDNA was 
0.85 (95% CI: 0.82–0.87) and the pooled negative predictive value (NPV) was 0.60 (95% CI: 0.56–0.63). The pos-
itive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 2.67 (95% CI: 1.86–3.82) and 0.46 (95% CI: 
0.38–0.54), respectively. The pooled diagnostic odds ratio (DOR) was 7.27 (4.39–12.05) and the area under the 
curve (AUC) of the summary receiver operating characteristics (sROC) curve was 0.77 (Fig. 3). Subgroup analysis 
was performed to investigate if the sample size and the different detection methods could significantly influence 
the diagnostic accuracy of ctDNA analysis and the results are shown in Figs 4 and 5 and reported in Table 2.
Study (reference)
Number of 
patients Assay Sensitivity n. (%) Specificity n. (%) PPV n. (%) NPV n. (%)
Ishii et al.18 18 Droplet dPCR 9/11 (81.8) 6/7 (85.7) 9/10 (90) 6/8 (75)
Thress et al.19 65 RT-PCR (cobas)BEAMing dPCR
30/41 (73)
33/41 (81)
16/24 (67)
14/24 (58)
30/38 (79)
33/43 (76.7)
16/27 (59.3)
14/22 (63.6)
Karlovich et al.20 95 RT-PCR (cobas)BEAMing dPCR
21/33 (64)
33/45 (73)
61/62 (98)
9/18
21/22 (95.5)
33/42 (78.6)
61/73 (83.6)
9/21 (42.9)
Oxnard et al.17 216 BEAMing dPCR 111/158 (70.3) 40/58 (69) 111/129 (86) 40/87 (46)
Reckamp et al.21 105 NGS 38/41 (93) 60/64 (94) 38/42 (90.5) 60/63 (95.2)
Sacher et al.22 54 Droplet dPCR 27/35 (77) 12/19 (63) 27/34 (79.4) 12/20 (60)
Sundaresan et al.23 25 RT-PCR (cobas) 6/10 (60) 9/15 (60) 6/12 (50) 9/13 (69.2)
Takahama et al.24 41 Droplet dPCR 20/31 (65) 7/10 (70) 20/23 (87) 7/18 (38.9)
Paweletz et al.25 14 NGS 8/10 (80) 2/4 (50) 8/10 (80) 2/4 (50)
Seki et al.26 10 Droplet dPCR 5/7 (71) 3/3 (100) 5/5 (100) 3/5(60)
Thompson et al.27 50 NGS 2/4 (50) 40/46 (87) 2/8 (25) 40/42 (95.2)
Suzawa et al.28 59 Droplet dPCR 9/21 (36) 37/38 (97) 9/10 (90) 37/49 (75.5)
Jenkins et al.29 543 RT-PCR (cobas) 255/416 (61.4) 100/127 (78.6) 255/282 (90.4) 100/261 (38.3)
Wang et al.30 16 Droplet dPCR 6/9 (66.7) 5/7 (71.4) 6/8 (75) 5/8 (62.5)
Mellert et al.31 55 Droplet dPCR 13/15 (87) 40/40 (100) 13/13 (100) 40/42 (95.2)
Kasahara et al.32 20 Chip-based dPCR 5/7 (71 7/13 (54) 5/11 (45.5) 7/9 (77.8)
Yoshida et al.33 21 PNA-LNA PCR 4/10 (40) 11/11 (100) 4/4 (100) 11/17 (64.7)
Wu et al.34 24 RT-PCR 7/17 (41) 5/7 (71) 7/9 (77.8) 5/15 (33.3)
Buder et al.35 45 Droplet dPCR 28/34 (82) 2/11 (18) 28/37 (75.7) 2/8 (25)
Table 1. Characteristics of Trials Included in the Meta-Analysis. RT-PCR: real-time PCR; dPCR: digital-PCR; 
NGS: next-generation sequencing; CI: confidence intervals; PPV: positive predictive value; NPV: negative 
predictive value.
Figure 2. Forest plots of sensitivity and specificity of ctDNA for the detection of EGFR-T790M mutation; *RT-
PCR; **dPCR.
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Threshold effect and heterogeneity. Spearman correlation coefficient and p-value were calculated to 
assess the threshold effect by Meta-DiSc meta-analysis software36. The Spearman correlation was 0.296 and the 
p value was 0.193 (>0.05), indicating that the threshold effect was not significant. Since a significant heteroge-
neity between studies caused by non-threshold has been detected, meta-regression was performed to identify 
the source of heterogeneity. However the results showed that both sample size and detection methods were not 
associated to heterogeneity.
Quality assessment of studies and publication bias. Egger’s regression test was performed to detect 
any publication bias. As shown in Fig. 6, no significant publication bias has been found (p = 0.11). The methodo-
logical quality of each trial was assessed by QUADAS-2, showing that the overall quality of included studies was 
good (Fig. 7).
Figure 3. SROC curve of ctDNA for detection of EGFR-T790M mutation.
Figure 4. Forest plots of sensitivity and specificity of ctDNA for the detection of EGFR-T790M mutation 
according to the different diagnostic methods: (A) (RT-PCR); (B) (dPCR); (C) (NGS).
www.nature.com/scientificreports/
5SCIentIFIC REPORTS | (2018) 8:13379 | DOI:10.1038/s41598-018-30780-4
Discussion
This meta-analysis included twenty-one studies (1639 patients) investigating the diagnostic accuracy of EGFR-T790M 
mutation testing by ctDNA in patients with advanced NSCLC who progressed to prior EGFR-TKI. The results of this 
work showed that ctDNA analysis is characterized by a pooled sensitivity of 0.67 and a pooled specificity of 0.80, while 
pooled PPV and NPV were 0.85 and 0.60, respectively. The ctDNA sensitivity was similar to that reported for the detec-
tion of EGFR-activating mutations14,15 and it is commonly considered adequate for a cancer screening test. It means 
that more than 30% of patients with a T790M-positive tissue biopsy will result negative on plasma test. Furthermore, 
as specifically shown by Jenkins et al. the false-negative rate may grow up to 50% in patients with intra-thoracic limited 
Figure 5. SROC curve of ctDNA for detection of EGFR-T790M mutation according to the different diagnostic 
methods: (A) (RT-PCR); (B) (dPCR); (C) (NGS).
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(M1a) disease29. For this reason, as recommended by Oxnard et al. any case of negative result on ctDNA analysis 
should be always confirmed by tumor tissue analysis17. Conversely, the ctDNA specificity emerged from this analy-
sis was somewhat lower than that observed for EGFR-activating mutations. Suboptimal specificity could be in part 
explained by the high intra-tumor heterogeneity, increasing the chances of “false negative” results by tumor tissue anal-
ysis. Oxnard et al. have recently demonstrated that a subgroup of plasma T790M-positive patients receiving osimer-
tinib in the AURA 1 study who were T790M-negative on tissue analysis had favorable clinical outcomes similarly to 
T790M-positive patients on tumor tissue17. Similarly 23/27 patients included in both AURA 1 and 2 studies who were 
initially detected as T790M-positive on plasma testing and T790M-negative by tumor tissue RT-PCR-based genotyping 
were confirmed to be T790M-positive by tissue NGS, showing favourable outcomes comparable to T790M-positive 
population37. Interestingly Chabon et al. identified additional molecular alterations by CAncer Personalized Profiling 
by deep Sequencing (CAPP-Seq) ctDNA analysis in 46% of patients who were T790M-positive on tumor tissue, includ-
ing cMET or HER2 increased gene copy number (GCN), and single nucleotide variations (SNVs) in EGFR, PIK3CA, 
or Rb1, suggesting that ctDNA analysis allows to more accurately identify the presence of multiple mechanisms of 
resistance emerging during TKI therapy38. Overall these data confirmed that the lower specificity of ctDNA observed 
in EGFR-TKI-resistant NSCLC patients could be partially related to the higher intra-tumor heterogeneity. Thus ctDNA 
should be considered as more representative of the overall tumor mutation status, allowing to identify plasma T790M 
mutations which may be missed on tissue biopsy. It is well known that both AUC and DOR are used as indicators to 
estimate the global performance of a diagnostic tests. According to the current guidelines39,40 the AUC of 0.77 and DOR 
of 7.27 reported in our analysis are not high enough to suggest an elevated diagnostic accuracy of ctDNA analysis of 
T790M. Similarly both the positive and the negative likelihood ratios suggested that ctDNA did not accurately detect 
the presence of T790M mutation in the plasma of NSCLC patients. The heterogeneity of analyzed studies, including 
different sample size as well as different practices and timing for both tumor and plasma sample collection and testing 
could have negatively influenced the overall results of this work. A stratified analysis was performed to investigate the 
impact of specific detection methods on the diagnostic accuracy of ctDNA analysis. As reported in Fig. 4 the results of 
this analysis showed that dPCR is characterized by higher sensitivity but lower specificity as compared to the standard 
non-digital PCR technologies. These data are in line with the evidences emerged from two selected trials19,20 directly 
comparing the diagnostic performance of BEAMing dPCR to cobas RT-PCR. Interestingly NGS revealed the highest 
accuracy to identify plasma T790M as compared to other detection platforms. This is likely due to the very high sen-
sitivity of NGS showing the ability to detect mutations at an allele fraction <1% both in tissue and plasma samples25. 
The use of NGS would likely allow to overcome the two main causes of EGFR mutation status discordance between 
tissue and plasma analysis, such as the intra-tumor heterogeneity and the low sensitivity of the standard diagnostic 
Sensitivity (95% 
CI)
Specificity (95% 
CI) PLR (95% CI) NLR (95% CI) DOR (95% CI)
AUC (95% 
CI)
All Studies 0.67 (0.64–0.70) 0.80 (0.77–0.83) 2.67 (1.86–3.82) 0.46 (0.38–0.54) 7.27 (4.39–12.05) 0.78
Sample size Large Studies (>60 patients) 0.67 (0.64–0.71) 0.80 (0.75–0.84) 3.01 (1.86–4.89) 0.39 (0.30–0.52) 9.69 (4.36–21.55) 0.82
Sample size Small Studies (<60 patients) 0.67 (0.61–0.74) 0.81 (0.75–0.85) 2.48 (1.46–4.22) 0.53 (0.44–0.65) 5.66 (2.91–10.99) 0.74
Detection Method (RT-PCR) 0.61 (0.57–0.65) 0.82 (0.77–0.87) 2.71 (1.51–4.87) 0.50 (0.42–0.61) 6.28 (2.15–14.58) 0.70
Detection Method (dPCR) 0.72 (0.68–0.76) 0.73 (0.67–0.79) 2.16 (1.42–3.27) 0.45 (0.38–0.54) 5.67 (3.22–9.98) 0.77
Detection Method (NGS) 0.87 (0.76–0.95) 0.89 (0.82–0.94) 4.55 (1.00–20.83) 0.26 (0.06–1.20) 19.53 (1.44–264.76) 0.88
Table 2. Meta-Analysis Results. CI: confidence intervals; RT-PCR: real-time PCR; dPCR: digital-PCR; NGS: 
next generation sequencing; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic 
odds ratio; AUC: area under curve.
Figure 6. Funnel plot of diagnostic odds ratio (DOR) for ctDNA detection of EGFR-T790M mutation. Each 
study is represented by one circle- the vertical line represents the pooled effect estimate.
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techniques. However the low number of studies as well as the small sample sizes of the analyzed population in the NGS 
subgroup might have biased the results, which need to be cautiously interpreted. Worth of mention is also the wide 
range of positivity thresholds used to detect T790M in both digital and non-digital PCR studies, which represents a 
major factor influencing both the sensitivity and specificity of a diagnostic test. Additional studies are urgently needed 
to standardize and improve technical approach and to identify the minimum biological threshold with clinical rele-
vance to guide treatment decisions in clinical practice. Finally some studies and a recent meta-analysis41 confirmed that 
the ability to identify EGFR-T790M mutation in ctDNA significantly varies by the extent of disease, suggesting that 
higher T790M rate is related to high ctDNA levels regardless of used diagnostic methods. Thus major efforts are needed 
to select the ideal subset of patients candidate to liquid biopsy where plasma testing could definitively replace tumor 
tissue analysis. In conclusion this is the first meta-analysis of the diagnostic performance of cfDNA for the detection of 
EGFR-T790M mutation status in NSCLC patients who progressed to EGFR-TKIs and represents an attempt to provide 
guidance for future studies. The development of standardized methodologies for ctDNA analysis and clinical validation 
in prospective trials with large cohorts of patients should be warranted in the near future.
Figure 7. Quality assessment of studies by QUADAS-2.
www.nature.com/scientificreports/
8SCIentIFIC REPORTS | (2018) 8:13379 | DOI:10.1038/s41598-018-30780-4
Materials and Methods
Search for clinical trials. We searched for all published studies reporting the sensitivity and the specific-
ity of plasma-based EGFR-T790M mutation testing by ctDNA. We searched for clinical trials using Medline 
(PubMed), Embase-databases and Cochrane-Library up to March 2018. We used the following search terms: 
“EGFR”, “Epidermal growth factor receptor”, “T790M” “circulating tumor DNA”, “ctDNA”, “non-small cell lung 
cancer”, “NSCLC”, “lung cancer”. The search was limited to human studies in the English language. Relevant 
abstracts from the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology 
(ESMO), and World Conference on Lung Cancer (WCLC) were included. We also explored the ClinicalTrials.gov 
website (www.clinicaltrials.gov) to search for unpublished data.
Selection criteria. According to the aforementioned search, clinical trials were taken into account if they 
met the following inclusion criteria: 1) patients with histologically-proven diagnosis of advanced NSCLC; 2) 
patients with radiological confirmed progression disease to EGFR-TKI; 3) studies performing EGFR-T790M 
mutation testing in matched tumour tissue and plasma samples 4) studies evaluating both the sensitivity and the 
specificity of EGFR-T790M mutation testing by ctDNA analysis. We excluded ongoing studies in order to min-
imize the risk of bias. In case of articles or abstracts with multiple follow up reports over time, we selected those 
reporting the most updated data. We excluded also studies which did not simultaneously report both sensitivity 
and specificity of EGFR-T790M mutation testing by ctDNA analysis.
Data extraction. Data extraction and assessment was independently made by two different authors (F.P. 
and S.R.) and disagreements were solved by discussion with another author (M.D.M.). The following data were 
collected from eligible studies: first author name, journal and year of publication, study design, study treat-
ment, number of patients, baseline characteristics of patients (i.e. age, gender, stage, etc…), methods used for 
EGFR-T790M detection in ctDNA, true positive (TP), false negative (FN), true negative (TN), and false pos-
itive (FN) rates. When multiple methods were used to detect EGFR-T790M in ctDNA, all were extracted and 
described. The meta-analysis was designed according to the PRISMA - guidelines for reporting of systematic 
reviews42.
Quality assessment. The overall quality of the included studies was evaluated by the QUASAD-2 (quality 
assessment of diagnostic accuracy studies 2) by two different investigators, a tool designed to assess the quality 
of primary diagnostic accuracy studies, consisting of 4 different domains: patient selection, index test, reference 
standard, and flow and timing.
Statistical analysis. EGFR-T790M mutational status in tumor tissue was considered the “gold standard”. 
For each study, we tabulated the number of true positives (T790M mutation detected both in liquid biopsy and 
in tumor tissue), false positives (T790M mutation detected in liquid biopsy but not detected in tumor tissue), 
false negatives (T790M mutation detected in tumor tissue but not detected in liquid biopsy), and true negatives 
(T790M mutation neither detected in tumor tissue nor detected in liquid biopsy). These numbers of patients were 
used to calculate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive 
likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and corresponding 95% 
confidence intervals (95% CI). The PLR is calculated as: sensitivity/(1 − specificity), and represents the likelihood 
that a positive liquid biopsy for the T790M mutation result would be expected in a patient with T790M detected 
in tumor tissue, compared to the likelihood that that same result would be expected in a patient without T790M 
detected in tumor tissue. The NLR is calculated as (1 − sensitivity)/specificity, and represents the likelihood that 
a negative liquid biopsy for the T790M mutation result would be expected in a patient with T790M detected in 
tumor tissue, compared to the likelihood that that same result would be expected in a patient without T790M 
detected in tumor tissue. The DOR is a single measure of diagnostic test performance that combines both like-
lihood ratios, and is calculated as PLR/NLR; it expresses how much greater the odds of having EGFR T790M 
mutation detected in tumor tissue are for the people with a positive liquid biopsy than for the people with a 
negative liquid biopsy. Sensitivity, specificity, positive predictive value and negative predictive value were pooled 
as weighted averages in which the weight of each study is its sample size. Likelihood ratios and diagnostic odds 
ratios were pooled by the DerSimonian Laird method (random effects model) to incorporate variation among 
studies. In addition, we generated a summary receiver operating characteristics (sROC) curve and calculated the 
area under the curve (AUC) of the sROC. Sub-group analyses were performed for sample size (dividing studies 
in smaller than 60 and larger than 60 patients) and detection methods (real-time PCR (RT-PCR), digital-PCR 
(dPCR), next-generation sequencing (NGS)). The Spearman correlation between the logit of sensitivity and logit 
of 1-specificity was calculated to determine the effect of threshold, and a P value < 0.05 indicated significant 
threshold effect. The heterogeneity (variation in study outcomes between studies) caused by non-threshold effect 
was measured by the Q test, which is calculated as the weighted sum of squared differences between individual 
study effects and the pooled effect across studies, and the inconsistency index (I2), which describes the percentage 
of variation across studies that is due to heterogeneity rather than chance. A P-value < 0.05 and a I2 value > 50% 
indicated significant heterogeneity. Meta-regression analysis was performed to identify the source of heterogene-
ity. As regards the risk of bias across studies, we performed a publication bias analysis using the visual inspection 
of the Funnel Plot and the Egger’s test. A P-value < 0.05 indicated significant publication bias. Publication bias 
analyses was performed by MetaEssentials software36. All other statistical analyses were performed using the 
Meta-DiSc software (version 1.4)36.
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